[CanSino: It is developing mRNA preventive vaccines and therapeutic biological products, as well as the development of related delivery systems] On September 30, CanSino (688185.SH) issued an announcement of abnormal stock trading fluctuations. The company is concerned about the recent development of mRNA technology in the market, and overseas clinical phase data of mRNA tumor vaccines have been released or planned to be made public. The mRNA platform is one of the technology platforms deployed by the company. The company is developing mRNA preventive vaccines and therapeutic biological products, as well as related delivery systems. In terms of therapeutic areas, the company is advancing the research and development of mRNA vaccines for the treatment of indications such as glioblastoma, rhabdomyosarcoma and cervical cancer, as well as the development of InVivoCAR-related therapies, which are currently in early stages.